Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Skin and subcutaneous tissue disorders – page 7

  • 849 clinical trials
  • 267 recruiting
  • 359 conditions
  • 25 countries

Conditions in this area

359 conditions with trials, the busiest first

Dermatitis atopic89Malignant melanoma79Systemic lupus erythematosus63Psoriasis54Hidradenitis47Psoriatic arthropathy46Systemic scleroderma40Metastatic malignant melanoma32Vitiligo24Hereditary angioedema22Chronic spontaneous urticaria19Malignant melanoma stage III17Dermatomyositis16Non-small cell lung cancer15Alopecia areata14Cutaneous lupus erythematosus14Rheumatoid arthritis14Basal cell carcinoma12Diabetic foot12Malignant melanoma stage IV12Actinic keratosis11Hepatocellular carcinoma11Neurodermatitis11Squamous cell carcinoma of skin11+335

Clinical trials in Skin and subcutaneous tissue disorders

849 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

849 clinical trials

Cutaneous T-cell lymphoma recurrent+1

Recruiting

A Study of PTX-100 for Patients with Cutaneous T-Cell Lymphoma That Has Returned or Did Not Respond to Previous Treatment

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Prescient Therapeutics Limited

Neurofibromatosis+1

Recruiting

A study of mirdametinib for infants and toddlers under 24 months of age with neurofibromatosis type 1 associated plexiform neurofibromas

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Sponsor:Merck Healthcare KGaA

Dermatitis atopic

Recruiting

Testing two moisturizing creams with urea, propylene glycol, and propylene glycol alone for preventing flare-ups in patients with atopic dermatitis

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Propylene Glycol
  • Sponsor:Galenica AB

Malignant melanoma

Recruiting

A Study Comparing MB11 and Nivolumab in Adults With Previously Untreated Advanced or Metastatic Melanoma

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Mabxience Research S.L.

Systemic scleroderma+3

Recruiting

A Study of Idecabtagene Vicleucel CAR-T Cell Therapy for Patients with Autoimmune Diseases That Did Not Respond to B Cell Removal Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Idecabtagene Vicleucel
  • Sponsor:Universitaetsklinikum Erlangen AöR

Dermatitis atopic

Recruiting

A study to evaluate the long-term safety and effectiveness of afimkibart in patients with atopic dermatitis who took part in previous afimkibart studies

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Cutaneous lupus erythematosus

Recruiting

Comparing lenalidomide and methotrexate for patients with difficult-to-treat cutaneous lupus erythematosus

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Assistance Publique Hopitaux De Paris

Hidradenitis

Recruiting

A Study of LAD191 Compared to Placebo and Adalimumab in Adults with Moderate-to-Severe Hidradenitis Suppurativa

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Adalimumab
  • Sponsor:Almirall S.A.

Acute graft versus host disease in skin

Recruiting

A study testing venetoclax for treating acute graft-versus-host disease in patients who received a stem cell transplant from a donor

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Venetoclax
  • Sponsor:Medical University Of Vienna

Systemic scleroderma

Recruiting

A Study Testing Anti-CD19 CAR T-Cell Therapy in Patients with Systemic Sclerosis Who Did Not Respond to Immunosuppressive Drugs

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Autologous T-Cells Transduced With Lentiviral Vector Expressing A Chimeric Antigen Receptor Directed Against Cd19
  • Sponsor:Centre Hospitalier Universitaire De Montpellier

Hereditary angioedema

Recruiting

A Study of ADX-324 to Prevent Attacks in Patients With Hereditary Angioedema

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ADX-324
  • Sponsor:Adarx Pharmaceuticals Inc.

Fabry's disease

Recruiting

Title: Evaluating low-dose prednisone with standard therapy to improve heart function in patients with cardiac manifestations of Fabry disease

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Medical University Of Lodz

Substances studied in this area

The therapies tested most often in Skin and subcutaneous tissue disorders trials.

Pembrolizumab57 clinical trialsNivolumab33 clinical trialsSodium Chloride22 clinical trialsDeucravacitinib19 clinical trialsCemiplimab18 clinical trialsUpadacitinib17 clinical trialsIpilimumab15 clinical trialsRituximab13 clinical trialsCyclophosphamide12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.